# Rectify Pharma

> Rectify Pharma is a clinical-stage biotechnology company developing oral small molecules called Positive Functional Modulators to restore or enhance membrane protein function. Its lead candidate, RTY-406, targets ABCB4 and BSEP for primary sclerosing cholangitis; its ABCC6 kidney-disease program is partnered with Boehringer Ingelheim.

- **Founded:** 2020
- **Headquarters:** Boston, United States
- **Founders:** Jonathan Moore (Founder and Chief Science Advisor), Jason Rhodes (Founding CEO; Atlas Venture partner)
- **Products:** PFM product platform, RTY-406, RTY-694, ABCC6 program / RTY-822, PC1/PC2 program
- **Notable:** Raised US$100 million Series A in October 2021., EASL 2025 hepatobiliary presentation selected for a Best of EASL Congress slide deck, according to the company., Signed Boehringer Ingelheim ABCC6 collaboration in December 2025.

## Products & services

- **PFM product platform** — Proprietary chemical libraries, functional assays and structural biology used to discover small molecules that directly bind membrane proteins and restore or enhance function.
- **RTY-406** — Investigational oral dual ABCB4/BSEP modulator for PSC; reported in Phase 1 by May 2026.
- **RTY-694** — Earlier disclosed hepatobiliary PFM with preclinical results presented at EASL 2025; current lead is RTY-406. No public explanation establishes why the candidate changed.
- **ABCC6 program / RTY-822** — Oral PFM program for CKD and pathological calcification; RTY-822 had positive rat-model results in 2025. ABCC6 research and licensing collaboration announced with Boehringer Ingelheim.
- **PC1/PC2 program** — Discovery program addressing autosomal dominant polycystic kidney disease.
- **ABCD1/ABCD2 program** — Neurology program targeting adrenomyeloneuropathy and adrenoleukodystrophy.

## Achievements

- Raised US$100 million Series A in October 2021.
- EASL 2025 hepatobiliary presentation selected for a Best of EASL Congress slide deck, according to the company.
- Signed Boehringer Ingelheim ABCC6 collaboration in December 2025.
- Advanced RTY-406 into Phase 1 in 2026.
- Reported cryo-EM confirmation of direct ABCB4/BSEP binding at ACS Fall 2026.

## Latest updates

- **2026-08** — Disclosed RTY-406 discovery, cryo-EM target-binding findings and mouse-model data at ACS Fall; reported ongoing Phase 1 study.
- **2026-07** — Appointed Constantine Chinoporos executive chairman following initiation of RTY-406 Phase 1.
- **2026-05** — Presented RTY-406 mouse and non-human-primate translational data at EASL.
- **2025-12** — Announced Boehringer Ingelheim CKD research and licensing agreement.

## Links

- Website: https://rectifypharma.com/
- LinkedIn: https://www.linkedin.com/company/rectify-pharma
- Twitter/X: https://x.com/RectifyPharma

---

Profile page: https://yespress.io/rectify-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-10-03